Ependymoma secondary prevention

Jump to: navigation, search

Ependymoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Epidemiology and Demographics

Risk Factors

Differentiating Ependymoma from other Diseases

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Staging

Laboratory Findings

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Ependymoma secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Ependymoma secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Ependymoma secondary prevention

CDC on Ependymoma secondary prevention

Ependymoma secondary prevention in the news

Blogs on Ependymoma secondary prevention</small>

Directions to Hospitals Treating Ependymoma

Risk calculators and risk factors for Ependymoma secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2]

Overview

Secondary prevention strategies following ependymoma include regular clinical assessment and neuroimaging.[1]

Secondary Prevention

  • Neuroimaging coupled with clinical assessment are generally recommended after treatment for ependymoma.[1]
  • MRI imaging of the brain and/or spinal cord every 3 months for the first 1 to 2 years after treatment.
  • After 2 years, imaging every 6 months for the next 3 years is often undertaken.

References


Linked-in.jpg